ReviewEClinicalMedicine2025
Neurosarcoidosis: a review from diagnosis and future perspectives.
Review in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychiatric manifestation of neurosarcoidosis: a systematic review with pooled descriptive analysis of case reports and case series.Rheumatology international · 2026Pooled it
- Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.Neurology · 2026Article
- Article
- Cerebral Foreign Body Granulomatous Reaction Secondary to Hydrophilic Polymer Embolization Post-Mechanical Thrombectomy: A Case Report and Overview of Differential Diagnosis.Stroke (Hoboken, N.J.) · 2026Article
- Rare Neurosarcoidosis Involvements.Respirology case reports · 2026Article
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- Cerebral toxoplasmosis: Parasitology, diagnosis, treatment, and prevention - a narrative review.Current research in parasitology & vector-borne diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is complicated by neurosarcoidosis in 5-15% of cases. Neurosarcoidosis is characterized by the presence of non-necrotizing granulomas that can affect any part of the nervous system. Key clinical presentations include chronic meningitis, cranial nerve palsies, parenchymal cerebral and spinal lesions, peripheral neuropathy, or myopathy. Diagnosis requires histopathological confirmation of granulomatous disease and exclusion of other potential diagnoses. Immunosuppressive treatment strategies are based on cohort studies and expert consensus, as randomized controlled trials are lacking. Neurosarcoidosis is associated with high morbidity, with only one third of patients being symptom-free status after treatment. Optimal care should be centralized to provide specialized multidisciplinary expertise and facilitate research. Future research should focus on the optimal timing of 3rd line treatment initiation and treatment personalization. Funding: The Netherlands Organisation for Health Research and Development (ZonMw), European Research Council.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.